Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avalo Therapeutics, Inc.AVTX · Entity 4936 | Director · Chief Executive Officer | May 21, 2026 | May 26, 2026 |
| Celldex Therapeutics, Inc.CLDX · Entity 4208 | Director | June 25, 2026 | June 29, 2026 |
| Oncternal Therapeutics, Inc.GTXI · Entity 89585 | Director | January 02, 2019 | January 03, 2019 |
| Zura Bio LtdZURA · Entity 5413 | Director | May 18, 2023 | May 23, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avalo Therapeutics, Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 190,314 |
Reported balance
After 2026-05-21 transaction · row 1
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 100,200 · Balance 190,314 F1: Represents performance stock units ("PSUs") granted to the Reporting Person on August 19, 2025. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals. As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents performance stock units ("PSUs") granted to the Reporting Person on August 19, 2025. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals. As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date.
Celldex Therapeutics, Inc.
Report date June 25, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.09 · Expires 2036-06-25 | Direct | 26,000 |
Reported balance
After 2026-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 26,000 · Balance 26,000 F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
Oncternal Therapeutics, Inc.
Report date January 02, 2019 · Filed January 03, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,759.211 |
Reported balance
After 2019-01-02 transaction · row 1
1 source rowRow 1 · 2019-01-02 · Grant · Acquired 14,534.884 · Balance 36,759.211 |
Zura Bio Ltd
Report date May 18, 2023 · Filed May 23, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.31 · Expires 2033-05-18 | Direct | 7,652 |
Reported balance
After 2023-05-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-05-18 · Grant · Acquired 7,652 · Balance 7,652 F1: The option shall vest and become fully exercisable on the earlier of (i) May 18, 2024 or (ii) the date of the next annual meeting of shareholders of Zura Bio Limited. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and become fully exercisable on the earlier of (i) May 18, 2024 or (ii) the date of the next annual meeting of shareholders of Zura Bio Limited.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARENA PHARMACEUTICALS INC
Report date March 11, 2022 · Filed March 11, 2022
Section 16 reporting ended · disclosed 2022-03-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-03-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-03-11 · Other · Disposed 8,150 · Balance 3,067 F1: Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. ("Parent") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock, $0.0001 par value per share ("Issuer Common Stock"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the "Merger Consideration"), subject to any required withholding of taxes. Row 2 · 2022-03-11 · Other · Disposed 3,067 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an "Issuer RSU"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.60 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-03-11 · Disposition to issuer · Disposed 7,500 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.60 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-03-11 · Disposition to issuer · Disposed 4,167 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.60 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-03-11 · Disposition to issuer · Disposed 15,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.17 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-03-11 · Disposition to issuer · Disposed 5,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.50 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-03-11 · Disposition to issuer · Disposed 5,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.31 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-03-11 · Disposition to issuer · Disposed 5,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $65.19 | Direct | 0 |
Reported balance
After 2022-03-11 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-03-11 · Disposition to issuer · Disposed 7,202 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition of Issuer common stock with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated December 12, 2021, by and among the Issuer, Pfizer Inc. ("Parent") and Antioch Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on March 11, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock, $0.0001 par value per share ("Issuer Common Stock"), was cancelled, retired and converted into the right to receive an amount equal to $100.00 in cash, without interest thereon (the "Merger Consideration"), subject to any required withholding of taxes.
F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit subject to vesting conditions based solely on continued employment or service to the Issuer or any of its subsidiaries granted by the Issuer under an Issuer Stock Plan, except any restricted stock unit that was granted after December 12, 2021, (each, an "Issuer RSU"), that was unvested and outstanding as of immediately prior to the Effective Time was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the Merger Consideration, subject to any required withholding of taxes.
F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Issuer Common Stock (each, an "Issuer Option") granted by Issuer under the Issuer's 2021 Long-Term Incentive Plan or prior stock plans (collectively, the "Issuer Stock Plans") that was outstanding as of immediately prior to the Effective Time, whether or not then vested, was cancelled and immediately ceased to be outstanding and was converted into the right to receive an amount in cash equal to the product of (1) the excess, if any, of the Merger Consideration over the per-share exercise price of such Issuer Option, multiplied by (2) the number of Issuer Common Stock then subject to such Issuer Option, subject to any required withholding of taxes.
Aevi Genomic Medicine, LLC
Report date February 03, 2020 · Filed February 05, 2020
Section 16 reporting ended · disclosed 2020-02-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 1
1 source rowRow 1 · 2020-02-03 · Disposition to issuer · Disposed 2,164,150 · Balance 0 F1: Disposed of as a result of the merger pursuant to the previously announced Agreement and Plan of Merger and Reorganization by and among Cerecor Inc. ("Cerecor"), Genie Merger Sub, Inc., Second Genie Merger Sub, LLC and issuer (the "Merger"). At the effective time of the Merger, holders of issuer common stock received (A) the fraction of a share of Cerecor common stock equal to the exchange ratio of 0.0334 (B) one contingent value right, which represents the right to receive contingent payments upon the achievement of certain milestones and (C) cash in lieu of any fractional shares of Cerecor common stock. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $4.22 · Expires 2023-09-13 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-02-03 · Disposition to issuer · Disposed 900,000 · Balance 0 F2: This option, which became exercisable on September 13, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $6.45 · Expires 2024-04-16 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-02-03 · Disposition to issuer · Disposed 13,532 · Balance 0 F3: This option, which became exercisable on April 16, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $7.01 · Expires 2025-02-18 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-02-03 · Disposition to issuer · Disposed 200,000 · Balance 0 F4: This option, which became exercisable on February 18, 2016, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $4.83 · Expires 2026-04-15 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-02-03 · Disposition to issuer · Disposed 200,000 · Balance 0 F5: This option, which became exercisable on April 15, 2017, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $4.91 · Expires 2027-02-17 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-02-03 · Disposition to issuer · Disposed 200,000 · Balance 0 F6: This option, which became exercisable on February 17, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $1.32 · Expires 2027-08-11 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-02-03 · Disposition to issuer · Disposed 100,000 · Balance 0 F7: The option, which became exercisable beginning on August 11, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $1.51 · Expires 2028-05-14 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-02-03 · Disposition to issuer · Disposed 300,000 · Balance 0 F9: The option, which became exercisable on May 14, 2019, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $1.55 · Expires 2028-04-17 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-02-03 · Disposition to issuer · Disposed 261,000 · Balance 0 F10: The option, which became exercisable on April 17, 2019, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. |
| Warrant (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $2.84 · Expires 2022-10-17 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-02-03 · Disposition to issuer · Disposed 13,334 · Balance 0 F8: This warrant, which was issued pursuant to a Securities Purchase Agreement dated August 9, 2017, was subsequently amended by the Amendment Agreement of Warrants to Purchase Common Stock dated December 5, 2019, whereby immediately prior to the Merger the warrants were automatically exercised in a cashless exercise. Given the exercise price of the outstanding warrants, the cashless exercise resulted in no shares of common stock being issued and the warrant was rendered null and void. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of as a result of the merger pursuant to the previously announced Agreement and Plan of Merger and Reorganization by and among Cerecor Inc. ("Cerecor"), Genie Merger Sub, Inc., Second Genie Merger Sub, LLC and issuer (the "Merger"). At the effective time of the Merger, holders of issuer common stock received (A) the fraction of a share of Cerecor common stock equal to the exchange ratio of 0.0334 (B) one contingent value right, which represents the right to receive contingent payments upon the achievement of certain milestones and (C) cash in lieu of any fractional shares of Cerecor common stock.
F2: This option, which became exercisable on September 13, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
F3: This option, which became exercisable on April 16, 2014, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
F4: This option, which became exercisable on February 18, 2016, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
F5: This option, which became exercisable on April 15, 2017, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
F6: This option, which became exercisable on February 17, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
F7: The option, which became exercisable beginning on August 11, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
F8: This warrant, which was issued pursuant to a Securities Purchase Agreement dated August 9, 2017, was subsequently amended by the Amendment Agreement of Warrants to Purchase Common Stock dated December 5, 2019, whereby immediately prior to the Merger the warrants were automatically exercised in a cashless exercise. Given the exercise price of the outstanding warrants, the cashless exercise resulted in no shares of common stock being issued and the warrant was rendered null and void.
F9: The option, which became exercisable on May 14, 2019, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
F10: The option, which became exercisable on April 17, 2019, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2020 Filed Feb 5, 2020 16:11 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | Disposition to issuerCommon Stock | 2,164,150 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-20-000109 · edgar.xml · nonDerivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of as a result of the merger pursuant to the previously announced Agreement and Plan of Merger and Reorganization by and among Cerecor Inc. ("Cerecor"), Genie Merger Sub, Inc., Second Genie Merger Sub, LLC and issuer (the "Merger"). At the effective time of the Merger, holders of issuer common stock received (A) the fraction of a share of Cerecor common stock equal to the exchange ratio of 0.0334 (B) one contingent value right, which represents the right to receive contingent payments upon the achievement of certain milestones and (C) cash in lieu of any fractional shares of Cerecor common stock. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:38 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 800,000 | $0.00 Strike: $3.98 | $0.00 |
DisclosureSEC source: 0001104659-20-011267 · tm206826d2_4.xml · derivative · entry 2 NEIL GARRY ARTHUR · CIK 0001586785 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800,000 Underlying: Common Stock · 800,000 shares Expires 2030-02-03 F2 · derivative.exercise_date: The stock option will vest over four years, with the first 25% vesting on the first anniversary of the grant date, and the remainder vesting in equal monthly installments, subject to the reporting person's continued service on each such vesting date. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:38 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantCommon Stock | 72,282 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-011267 · tm206826d2_4.xml · nonDerivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,282 F1 · price: Received in exchange for 2,164,150 shares of Aevi Genomic Medicine, Inc. ("Aevi") common stock in connection with the merger of Aevi into a wholly owned subsidiary of the issuer pursuant to the previously announced Agreement and Plan of Merger and Reorganization by and among Aevi, Genie Merger Sub, Inc., Second Merger Sub, LLC and the issuer. Read SEC document |
| December 05, 2019 Filed Dec 9, 2019 21:12 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | PurchaseCommon Stock | 2,049,376 | $0.13 | $274,616.38 |
DisclosureSEC source: 0001192482-19-000511 · edgar.xml · nonDerivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,164,150 Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 18:48 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $56.50 | $0.00 |
DisclosureSEC source: 0001209191-19-037495 · doc4.xml · derivative · entry 2 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2026-06-13 F2 · derivative.exercise_date: The options vest in 12 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over one year beginning on July 13, 2019, and are exercisable once vested. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 18:48 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantCommon Stock | 2,654 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-037495 · doc4.xml · nonDerivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,704 F1 · shares: The amount represents restricted stock units that vest in full on the earliest of June 13, 2020, or the date of Arena's next annual meeting of stockholders. The shares underlying the restricted stock units will be issued upon vesting of the restricted stock units. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 16:27 UTC | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | GrantCommon Stock | 14,534.884 | $0.86 | $12,500.00 |
DisclosureSEC source: 0001179110-19-000215 · edgar.xml · nonDerivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,759.211 Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 17:02 UTC | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | GrantCommon Stock | 8,333.333 | $1.50 | $12,500.00 |
DisclosureSEC source: 0001179110-18-011928 · edgar.xml · nonDerivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,224.327 Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 11:05 UTC | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | GrantCommon Stock | 808.016 | $15.47 | $12,500.01 |
DisclosureSEC source: 0001179110-18-009271 · edgar.xml · nonDerivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,890.994 Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 16:26 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | GrantStock Option (Right to Purchase) · Derivative | 261,000 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001192482-18-000303 · edgar.xml · derivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,000 Underlying: Common Stock · 261,000 shares Expires 2028-04-17 F1 · date: The option award was granted on April 17, 2018 and was subject to forfeiture if stockholder approval of a proposed amendment to the Issuer's stock incentive plan to increase the number of shares reserved for issuance under the plan was not obtained. The Issuer's stockholders approved the amendment to the Issuer's stock incentive plan at the Issuer's annual meeting of stockholders on June 14, 2018. F2 · derivative.exercise_date: The option award vests and becomes exercisable as follows (rounded up to the nearest whole share of common stock): one-third on April 17, 2019, then in 24 equal monthly installments on the 17th day of each subsequent calendar month, subject to the reporting person's continued service with the issuer. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 16:32 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $49.17 | $0.00 |
DisclosureSEC source: 0001209191-18-038076 · doc4.xml · derivative · entry 2 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2025-06-13 F2 · derivative.exercise_date: The options vest in 12 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over one year beginning on July 13, 2018, and are exercisable once vested. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 16:32 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantCommon Stock | 3,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-038076 · doc4.xml · nonDerivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,050 F1 · shares: The amount represents restricted stock units that vest in full on the earliest of June 13, 2019, or the date of Arena's next annual meeting of stockholders. The shares underlying the restricted stock units will be issued upon vesting of the restricted stock units. Read SEC document |
| May 14, 2018 Filed May 16, 2018 16:26 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | GrantStock Option (Right to Purchase) · Derivative | 300,000 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0001192482-18-000221 · edgar.xml · derivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2028-05-14 F1 · derivative.exercise_date: The option award vests and becomes exercisable as follows (rounded up to the nearest whole share of common stock): one-third on May 14, 2019, then in 24 equal monthly installments on the 14th day of each subsequent calendar month, subject to the reporting person's continued service with the issuer. Read SEC document |
| May 10, 2018 Filed May 11, 2018 16:17 UTC | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | GrantDirector Stock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $17.20 | $0.00 |
DisclosureSEC source: 0001179110-18-006644 · edgar.xml · derivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2028-05-09 F1 · derivative.exercise_date: The option vests in a series of three successive equal annual installments beginning on May 10, 2019. Read SEC document |
| April 02, 2018 Filed Apr 3, 2018 16:46 UTC | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | GrantCommon Stock | 715.512 | $17.47 | $12,499.99 |
DisclosureSEC source: 0001179110-18-005240 · edgar.xml · nonDerivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,082.978 Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 12:40 UTC | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | GrantCommon Stock | 1,090.75 | $11.46 | $12,500.00 |
DisclosureSEC source: 0001179110-18-000482 · edgar.xml · nonDerivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,367.466 Read SEC document |
| October 17, 2017 Filed Oct 18, 2017 16:16 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | PurchaseWarrant (right to buy) · Derivative | 13,344 | $0.00 Strike: $2.84 | $0.00 |
DisclosureSEC source: 0001144204-17-053027 · tv477166_4.xml · derivative · entry 2 NEIL GARRY ARTHUR · CIK 0001586785 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,344 Underlying: Common Stock · 13,344 shares Expires 2022-10-17 Read SEC document |
| October 17, 2017 Filed Oct 18, 2017 16:16 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | PurchaseCommon Stock | 75,000 | $1.26 | $94,500.00 |
DisclosureSEC source: 0001144204-17-053027 · tv477166_4.xml · nonDerivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,774 Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 16:06 UTC | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | GrantCommon Stock | 1,574.307 | $7.94 | $12,500.00 |
DisclosureSEC source: 0001179110-17-013089 · edgar.xml · nonDerivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,276.716 Read SEC document |
| August 11, 2017 Filed Aug 15, 2017 16:16 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | GrantStock Option (Right to Purchase) · Derivative | 400,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001144204-17-043511 · v473386_form4.xml · derivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2027-08-11 F1 · derivative.exercise_date: The option award vests and becomes exercisable as follows (rounded up to the nearest whole share of common stock): one-third on August 11, 2018, then in 24 equal monthly installments on the 11th day of each subsequent calendar month, subject to the reporting person's continued service with the issuer. Read SEC document |
| August 11, 2017 Filed May 16, 2018 16:21 UTC Amendment | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | GrantStock Option (Right to Purchase) · Derivative | 100,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001192482-18-000220 · edgar.xml · derivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-08-11 F2 · shares: Reflects a reduction in the number of shares purchaseable under the stock option. A portion of the originally granted amount was void due to having exceeded certain plan limitations. F1 · derivative.exercise_date: The option award vests and becomes exercisable as follows (rounded up to the nearest whole share of common stock): one-third on August 11, 2018, then in 24 equal monthly installments on the 11th day of each subsequent calendar month, subject to the reporting person's continued service with the issuer. F2 · derivative.underlying_shares: Reflects a reduction in the number of shares purchaseable under the stock option. A portion of the originally granted amount was void due to having exceeded certain plan limitations. F2 · balance_after: Reflects a reduction in the number of shares purchaseable under the stock option. A portion of the originally granted amount was void due to having exceeded certain plan limitations. Read SEC document |
| July 03, 2017 Filed Jul 5, 2017 17:50 UTC | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | GrantCommon Stock | 2,376.426 | $5.26 | $12,500.00 |
DisclosureSEC source: 0001179110-17-010006 · edgar.xml · nonDerivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,702.409 Read SEC document |
| June 13, 2017 Filed Jun 14, 2017 19:45 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantEmployee Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0001209191-17-039979 · doc4.xml · derivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2024-06-13 F1 · derivative.exercise_date: The options vest over one year with one twelfth vesting on July 13, 2017, and the remainder of the shares vesting monthly over the following eleven months in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested. Read SEC document |
| May 12, 2017 Filed May 15, 2017 17:02 UTC | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | GrantDirector Stock Option (Right to Buy) · Derivative | 11,250 | $0.00 Strike: $4.29 | $0.00 |
DisclosureSEC source: 0001179110-17-007186 · edgar.xml · derivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 11,250 shares Expires 2027-05-11 F1 · derivative.exercise_date: The option vests in a series of three successive equal annual installments beginning on May 12, 2018. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 16:58 UTC | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | GrantCommon Stock | 2,551.02 | $4.90 | $12,500.00 |
DisclosureSEC source: 0001179110-17-005780 · edgar.xml · nonDerivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,325.983 Read SEC document |
| February 17, 2017 Filed Feb 17, 2017 17:45 UTC | Aevi Genomic Medicine, LLC GNMX · Entity 148532 | GrantStock Option (Right to Purchase) · Derivative | 200,000 | $0.00 Strike: $4.91 | $0.00 |
DisclosureSEC source: 0001192482-17-000048 · edgar.xml · derivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2027-02-17 F1 · derivative.exercise_date: The option award vests and becomes exercisable in three equal installments (rounded up to the nearest whole share of common stock) on February 17, 2018, February 17, 2019 and February 17, 2020, subject to the reporting person's continued service with the issuer. Read SEC document |
| February 13, 2017 Filed Feb 14, 2017 20:18 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantEmployee Stock Option (right to buy) · Derivative | 41,666 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0001209191-17-010894 · doc4.xml · derivative · entry 2 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,666 Underlying: Common Stock · 41,666 shares Expires 2024-02-13 F2 · derivative.exercise_date: The options vest over four months with 25% vesting on March 13, 2017, and the remainder of the shares vesting monthly over the following three months in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested. Read SEC document |
| February 13, 2017 Filed Feb 14, 2017 20:18 UTC | ARENA PHARMACEUTICALS INC ARNA · Entity 94856 | GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0001209191-17-010894 · doc4.xml · derivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2024-02-13 F1 · derivative.exercise_date: The options vest over one year with one twelfth vesting on March 13, 2017, and the remainder of the shares vesting monthly over the following eleven months in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 17:03 UTC | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | GrantCommon Stock | 2,399.232 | $5.21 | $12,500.00 |
DisclosureSEC source: 0001179110-17-000262 · edgar.xml · nonDerivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,774.963 F1 · balance_after: On December 5, 2016, the Issuer effected a one-for-ten reverse stock split of its Common Stock (the "Reverse Split"). The number of securities beneficially owned by the Reporting Person has been adjusted to reflect the Reverse Split. Read SEC document |
| October 03, 2016 Filed Oct 4, 2016 17:02 UTC | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | GrantCommon Stock | 16,447.37 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-030308 · edgar.xml · nonDerivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,757.32 Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 17:02 UTC | Oncternal Therapeutics, Inc. GTXI · Entity 89585 | GrantCommon Stock | 7,309.95 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-029324 · edgar.xml · nonDerivative · entry 1 NEIL GARRY ARTHUR · CIK 0001586785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,309.95 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.